期刊文献+

C反应蛋白联合血浆纤维蛋白原检测对慢性阻塞性肺疾病急性加重期的诊断价值 被引量:2

Value of C-reactive Protein Combined with Plasma Fibrinogen Detection in Diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
下载PDF
导出
摘要 目的探讨C-反应蛋白和血浆纤维蛋白原的检测在慢性阻塞性肺病急性加重期诊断价值。方法采用病例对照研究,随机选择2015年1—8月在该院住院治疗的慢性阻塞性肺疾病患者98例,其中急性加重期56例(试验组)和稳定期42例(对照组),检测其血清C-反应蛋白和血浆纤维蛋白原水平。结果试验组C-反应蛋白(61.4±10.46)mg/L、血浆纤维蛋白原(5.9±1.15)g/L,对照组C-反应蛋白(8.2±3.62)mg/L,血浆纤维蛋白原(3.8±0.4 1)g/L,慢性阻塞性肺疾病急性加重期C-反应蛋白和血浆纤维蛋白原水平显著高于稳定期(P<0.01)。结论 C-反应蛋白和纤维蛋白原可作为慢性阻塞性肺病急性加重期患者感染早期诊断和病情监测的指标之一。C-反应蛋白检测值为(8.2±3.62) Objective To discuss the value of c-reactive protein combined with plasma fibrinogen detection in diagnosis of acute exacerbation of chronic obstructive pulmonary disease. Methods 98 cases of inpatients with chronic obstructive pulmonary disease treated in our hospital from January 2015 to August 2015 were randomly selected and divided into the test group with 56 cases (acute exacerbation phase) and the control group with 42 cases (slationary phase), the serum c- reactive proteins and plasma fibrinogen levels were detected. Results The c-reactive protein and plasma fibrinogen levels were respectively (61.4±10.46) mg/L and (5.9±1.15) g/L in the test group and (8.2±3.62) mg/L and (3.8±0.4 1) g/L in the control group, the c-reactive protein and plasma fibrinogen levels of chronic obstructive pulmonary disease in the acute exacerbation phase were obviously higher than those in the slationary phase (P〈O.O1). Conclusion The c-reactive protein and plasma fibrinogen can be used as one of the indexes of early diagnosis and disease monitoring of patients with acute exacerbation of chronic obstructive pulmonary disease, and the detection value of c-reactive protein was (8.2±3.62) mg/L.
作者 莫军 肖荣琼
出处 《中外医疗》 2016年第9期179-181,共3页 China & Foreign Medical Treatment
关键词 C-反应蛋白 纤维蛋白原 慢性阻塞性肺疾病 急性加重期 C-reactive protein Plasma fibrinogen Chronic obstructive pulmonary disease Acute exacerbation phase
  • 相关文献

参考文献8

二级参考文献44

  • 1吴尚洁,陈平,蒋惜念,刘志军.慢性阻塞性肺疾病患者C反应蛋白水平及其与肺功能变化的相关性[J].中南大学学报(医学版),2005,30(4):444-446. 被引量:45
  • 2胡伟贞,陈小龙,朱金霞.COPD急性加重期患者血清IL-8与C反应蛋白变化及临床意义[J].临床肺科杂志,2007,12(1):19-20. 被引量:26
  • 3慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8233
  • 4Wedzicha JA,Seemungal TA.COPD exacerbations:defining their cause and prevention.Lancet,2007,370(9589):786-796.
  • 5Povoa P,Almeida E,Moreira P,et al. C-reactive protein as an indica- tor of sepsis[ J ]. Intensive Care Med, 1998,24 (10) : 1052 - 1056.
  • 6Hurst JR, Perera WR,Wilkinson TM,et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmo- nary disease[J]. Am J Respir Cfit Care Med,2006,173( 1 ) :71 -78.
  • 7Keating GM, McCormack PL. Salmeterol/flutieasone propionate: a re- view of its use in the treatment of chronic obstructive pulmonary disease [J]. Drugs, 2007,67(16) :2383 -2405.
  • 8Balkissoon R, Make B. A double - blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plusalbuterol 180 μg pm q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours inpatients with chronic obstructive pulmo- nary disease[J]. COPD, 2008,5(4) :221 -227.
  • 9Evans TW. International Consensus Conferences in Intensive Care Medi- cine: non - invasive positive pressure ventilation in acute respiratory failure. Organised jointly by the American Thoracic Society, the Euro- pean Respiratory Society, the European Society of Intensive Care Medi- cine, and the Societe de Reanimation de Langue Fran? aise, and ap- proved by the ATS Board of Directors, December 2000 [ J ]. Intensive Care Med, 2001,27 ( 1 ) : 166 - 178.
  • 10Keam SJ, Keating GM. Tiotropium bromide. A review of its use as ma- intenance therapy in patients with C OPD [ J]. Treat Respir Med, 2004, 3(4) :247 -268.

共引文献55

同被引文献10

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部